A phase 3 study demonstrated that ritlecitinib was effective and well tolerated in patients with alopecia areata and ≥ 25% ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

Panelists discuss how the data from the BRAVE-AA1 and BRAVE-AA2 phase 3 trials demonstrated the safety and efficacy of baricitinib, leading to its FDA approval in 2022 as the first systemic treatment ...

Another treatment is Litfulo, a pill from drug manufacturer Pfizer for people ages 12 and older with severe alopecia areata. Right now, Tisdale isn’t taking Litfulo or any other prescriptions to ...

Pfizer has picked up approval in the EU for Litfulo, its JAK inhibitor for severe alopecia areata, extending its challenge to Eli Lilly’s first-to-market Olumiant. The European Commission has ...

Pfizer’s Litfulo is the first treatment approved for treating adolescents with severe alopecia areata. The drug’s approval also covers adults, were it will compete against Eli Lilly’s Olumiant.

Panelists discuss how switching therapies in patients with alopecia areata (AA) is often necessary when initial treatments ...

The actress and singer was diagnosed with alopecia areata in her mid-20s For Ashley Tisdale, making changes to her haircare routine was all a part of being diagnosed with alopecia. The actress and ...

In June 2023, Pfizer's LITFULOTM (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata received FDA approval. The medication, known by the brand name Litfulo, has been approved for ...

DelveInsight's Alopecia Areata Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM. LAS VEGAS, NV, UNITED STATES, January 15, 2025 /EINPresswire ...